• Americans are turning to peptides at an unprecedented rate without any clinical evidence that they are safe or effective.

  • Importing medicine from Canada's or other countries' drug supplies isn't safe or cost-effective.

  • More than a decade into the counterfeit pill crisis, fake prescription pills made with deadly ingredients are still killing Americans. 

  • Overwhelming demand for transformative GLP-1s has led to widespread illicit compounding and a boom in counterfeiting.

  • Several states are trying to to set price caps to reduce the cost of expensive medicine, but this could bankrupt pharmacies and threaten patient access.

July 20, 2026: North Carolina woman shares experience with hospitalization after telehealth prescribed weight loss drugs

July 21, 2026

She was given a dramatic increase in her prescribed dose, a change she questioned, but was told to follow the doctor’s instructions. Despite injecting a smaller amount than directed, she began violently vomiting within hours.

Live event on safety on compounded GLP-1s

July 20, 2026

Join us in person in Washington DC on Wednesday July 26, 2026 for Axios Live “Examining Risk and Regulation in the GLP-1 Landscape” Speakers include The Honorable Nikki Budzinski (IL-13), Scott Kahan, M.D., M.P.H., F.T.O.S., Shabbir Imber Safdar, CFE, The Honorable Rudy Yakym (IN-02)

July 13, 2026: Researchers find telehealth platforms prioritize “quick prescriptions over comprehensive care”

July 16, 2026

The study found that 91.8% of the platforms issued a prescription. In their questionnaire, which was used on every platorm, 98% asked about medical conditions, 93.9% asked about medications and allergies, and only 55.1% asked about eating disorder history.

The five risks of taking unapproved peptides

July 13, 2026

The FDA is reconsidering adding a dozen peptides—seven in July; another four next February—to its Section 503A bulk drug substances list after excluding them over safety concerns in 2023. The review is happening at a time when Americans are turning to peptides at an unprecedented rate, driven by grifters in the online wellness space, who push these products for a profit without any clinical evidence they are either safe or effective.

Partnership for Safe Medicines urges FDA advisory committee to reject compounding of unapproved peptides

July 10, 2026

On July 23-24, the FDA will evaluate seven peptides for custom pharmacy compounding. Citing a critical deficit in human safety data, widespread consumer confusion, and systemic supply chain vulnerabilities, PSM urges the committee to block mass compounding and protect patient safety.

July 6, 2026: Judge blocks Colorado price cap on Enbrel

July 7, 2026

The nations first upper payment limit, set to take effect in January 2027, has been temporarily paused. Chief Judge Daniel Domenico said Amgen would face significant and irreparable harm because of the price cap, and found that federal patent law likely preempted a state price cap, reported Reuters.

June 29, 2026: PSM releases road map to improve patient safety amidst compounding boom

June 30, 2026

A Call to Action: Restoring and Strengthening America’s Patient Safety System presents a two pillar system for regulators and lawmakers to preserve the FDAs gold standard.

Like your information on video? Subscribe to our YouTube playlist!

youtube-video-thumbnail
youtube-video-thumbnail

PDABs spend millions. Are payment caps even working?

youtube-video-thumbnail

PSM spoke with Tencount Consulting's Mark Karhoff about DSCSA enforcement and the changeover from 10 to 12 digit NDC codes.

Click the images below to see more recent videos.